Health ❯ Healthcare ❯ Patient Outcomes ❯ Progression-Free Survival

Treatment Efficacy

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer